OPKO Health Inc. (OPK) is focused on developing and commercializing health diagnostics tests, vaccines to diagnose, treat, and prevent neurological disorders, and other pharmaceutical products. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida. This company has management that has proven to be very successful in the past. Phillip Frost, M.D. is the CEO of OPKO and he formerly was the CEO of Ivax before it was acquired by Teva Pharmaceutical Industries Ltd. (TEVA). Dr. Frost is currently also the Chairman of the Board for Teva Pharmaceuticals and it is possible that OPKO might be a price buyout target for Teva someday. Dr. Frost and other insiders have spent over $10 million buying OPK shares in 2011. This kind of insider buying is rare. It shows confidence and a high level of commitment by management.
Catalysts: Positive clinical data and additional partnership agreements, or a buyout offer.
52 week range: $2.86 to $5.85
12 Month Target Price: $8 Long-Term Target Price: $10